Literature DB >> 15900944

Hemodynamic effects of orally administered carvedilol in healthy conscious dogs.

Jonathan A Abbott1, Richard V Broadstone, Daniel L Ward, R Lee Pyle.   

Abstract

OBJECTIVE: To evaluate the hemodynamic effects of orally administered carvedilol in healthy dogs with doses that might be used to initiate treatment in dogs with congestive heart failure. ANIMALS: 24 healthy dogs. PROCEDURE: Dogs were randomly allocated to receive carvedilol PO at a dose of 1.56, 3.125, or 12.5 mg, twice daily for 7 to 10 days; 6 dogs served as controls. Investigators were blinded to group assignment. Hemodynamic variables were recorded prior to administration of the drug on day 1 and then 2, 4, and 6 hours after the morning dose on day 1 and days 7 to 10. Change in heart rate after IV administration of 1microg of isoproterenol/kg and change in systemic arterial blood pressure after IV administration of 8 microg of phenylephrine/kg were recorded 2 and 6 hours after administration of carvedilol.
RESULTS: Administration of carvedilol did not significantly affect resting hemodynamic variables or response to phenylephrine. The interaction of day and carvedilol dose had a significant effect on resting heart rate, but a significant main effect of carvedilol dose on resting heart rate was not detected. Increasing carvedilol dose resulted in a significant linear decrease in heart rate response to isoproterenol. CONCLUSIONS AND CLINICAL RELEVANCE: In healthy conscious dogs, orally administered carvedilol at mean doses from 0.08 to 0.54 mg/kg given twice daily did not affect resting hemodynamics. Over the dose range evaluated, there was a dose-dependent attenuation of the response to isoproterenol, which provided evidence of beta-adrenergic receptor antagonism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15900944     DOI: 10.2460/ajvr.2005.66.637

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  4 in total

1.  Application of carvedilol in a dog with pseudoephedrine toxicosis-induced tachycardia.

Authors:  Min-Hee Kang; Hee-Myung Park
Journal:  Can Vet J       Date:  2012-07       Impact factor: 1.008

2.  Ivabradine reduces heart rate while preserving metabolic fluxes and energy status of healthy normoxic working hearts.

Authors:  Benjamin Lauzier; Fanny Vaillant; Roselle Gélinas; Bertrand Bouchard; Roger Brownsey; Eric Thorin; Jean-Claude Tardif; Christine Des Rosiers
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-21       Impact factor: 4.733

3.  Short-term follow-up of exercise training program and beta-blocker treatment on quality of life in dogs with naturally acquired chronic mitral valve disease.

Authors:  M Marcondes-Santos; A P Mansur; F S Fragata; C M C Strunz
Journal:  Braz J Med Biol Res       Date:  2015-08-04       Impact factor: 2.590

Review 4.  Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020.

Authors:  Mara Bagardi; Viola Zamboni; Chiara Locatelli; Alberto Galizzi; Sara Ghilardi; Paola G Brambilla
Journal:  Animals (Basel)       Date:  2022-01-16       Impact factor: 2.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.